Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia Health System, Charlottesville, Va 22908-1414, USA.
Hypertension. 2010 Feb;55(2):474-80. doi: 10.1161/HYPERTENSIONAHA.109.144956. Epub 2009 Dec 7.
The preferred ligand of angiotensin (Ang) II type 2 (AT(2)R)-mediated natriuresis is Ang III. The major enzyme responsible for the metabolism of Ang III is aminopeptidase N, which is selectively inhibited by compound PC-18. In this study, urine sodium excretion rates (U(Na)V), fractional excretion of sodium, fractional excretion of lithium, glomerular filtration rate, and mean arterial pressures were studied in prehypertensive and hypertensive spontaneously hypertensive rats (SHRs) and compared with age-matched Wistar-Kyoto rats (WKYs). Although renal interstitial infusion of Ang II type 1 receptor blocker candesartan increased U(Na)V in WKYs from a baseline of 0.05+/-0.01 to 0.17+/-0.04 micromol/min (P<0.01), identical infusions failed to increase U(Na)V in hypertensive SHRs. Coinfusion of AT(2)R antagonist PD-123319 abolished the natriuretic responses to candesartan in WKYs, indicating an AT(2)R-mediated effect. AT(2)R-mediated natriuresis was enabled in hypertensive SHRs by inhibiting the metabolism of Ang III with PC-18 (0.05+/-0.01 to 0.11+/-0.03 micromol/min; P<0.05). The defects in sodium excretion were present before the onset of hypertension in SHRs, because young WKYs demonstrated double the U(Na)V of SHRs (0.04+/-0.006 versus 0.02+/-0.003 micromol/min; P<0.01) at baseline. The increased U(Na)V of young WKYs was attributed to reduced renal proximal tubule sodium reabsorption, because increases in fractional excretion of sodium were paralleled by increases in fractional excretion of lithium. Renal interstitial PC-18 infusion ameliorated defective AT(2)R-mediated natriuresis in young SHRs by increasing fractional excretion of sodium and fractional excretion of lithium without changing the glomerular filtration rate. Thus, increased renal proximal tubule sodium retention is observed before the onset of hypertension in SHRs, and inhibition of the metabolism of Ang III ameliorates this pathophysiologic defect in sodium excretion.
血管紧张素(Ang)II 型 2(AT(2)R)介导的利钠作用的首选配体是 Ang III。负责 Ang III 代谢的主要酶是氨基肽酶 N,它被化合物 PC-18 选择性抑制。在这项研究中,研究了预高血压和高血压自发性高血压大鼠(SHR)的尿钠排泄率(U(Na)V)、钠排泄分数、锂排泄分数、肾小球滤过率和平均动脉压,并与年龄匹配的 Wistar-Kyoto 大鼠(WKY)进行了比较。尽管肾间质输注血管紧张素 II 型 1 受体阻滞剂坎地沙坦可使 WKY 的 U(Na)V 从基线的 0.05+/-0.01 增加到 0.17+/-0.04 umol/min(P<0.01),但相同的输注未能增加高血压 SHR 的 U(Na)V。AT(2)R 拮抗剂 PD-123319 的共输注消除了坎地沙坦在 WKY 中的利钠反应,表明存在 AT(2)R 介导的作用。通过用 PC-18 抑制 Ang III 的代谢,使高血压 SHR 中的 AT(2)R 介导的利钠作用成为可能(0.05+/-0.01 至 0.11+/-0.03 umol/min;P<0.05)。在 SHR 发生高血压之前,钠排泄的缺陷就已经存在,因为年轻的 WKY 的 U(Na)V 是 SHR 的两倍(0.04+/-0.006 与 0.02+/-0.003 umol/min;P<0.01)。年轻 WKY 的 U(Na)V 增加归因于肾近端小管钠重吸收减少,因为钠排泄分数的增加与锂排泄分数的增加平行。肾间质 PC-18 输注通过增加钠排泄分数和锂排泄分数来改善年轻 SHR 中缺陷的 AT(2)R 介导的利钠作用,而不改变肾小球滤过率。因此,在 SHR 发生高血压之前,就观察到肾近端小管钠重吸收增加,抑制 Ang III 的代谢可改善钠排泄的这种病理生理缺陷。